Decheng Capital Reduces Stake in 4D Molecular Therapeutics

Hedge fund cuts holdings in gene therapy company by over 60%

Mar. 16, 2026 at 9:50am

Got story updates? Submit your updates here. ›

Decheng Capital LLC, a hedge fund, has reduced its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 61.3% in the third quarter, according to a recent SEC filing. The fund now owns 92,748 shares of the gene therapy company's stock, down from 239,510 shares previously.

Why it matters

This reduction in Decheng Capital's position in 4D Molecular Therapeutics could signal a shift in investor sentiment towards the company and its gene therapy pipeline. As a major institutional investor, Decheng's portfolio moves can influence market perceptions of the stock.

The details

According to the SEC filing, Decheng Capital sold 146,762 shares of 4D Molecular Therapeutics during the third quarter, reducing its total stake to 92,748 shares. This represents approximately 0.16% of the company's outstanding shares. 4D Molecular Therapeutics is a clinical-stage biotechnology company focused on developing targeted gene therapies for rare diseases.

  • Decheng Capital reduced its stake in 4D Molecular Therapeutics during the third quarter of 2026.

The players

Decheng Capital LLC

A hedge fund that has reduced its position in 4D Molecular Therapeutics by over 60%.

4D Molecular Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing targeted gene therapies for rare diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Decheng Capital's stake in 4D Molecular Therapeutics could signal a shift in investor sentiment towards the company and its gene therapy pipeline. As a major institutional investor, Decheng's portfolio moves can influence market perceptions of the stock.